Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-11
2005-10-11
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S214020, C514S250000, C514S290000, C514S292000, C514S411000, C540S558000, C540S559000, C540S561000, C540S586000, C544S344000, C546S079000, C546S084000, C546S101000, C548S427000
Reexamination Certificate
active
06953791
ABSTRACT:
This invention is directed to compounds of the formulaand the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of Formula I.
REFERENCES:
patent: 4411890 (1983-10-01), Momany
patent: 6251902 (2001-06-01), Carpino et al.
patent: 6297380 (2001-10-01), Chiu et al.
patent: WO9411012 (1994-05-01), None
patent: WO9413696 (1994-06-01), None
patent: WO9513069 (1995-05-01), None
patent: WO9709060 (1997-03-01), None
patent: WO9724369 (1997-07-01), None
patent: WO9734604 (1997-09-01), None
Maccario, et al. “Metabolic Modulation of the Growth Hormone-Releasing Activity of Hexarelin in Man”,Metabolism44(1), pp. 134-138 (1995).
Jorgensen, et al. “Beneficial Effects of Growth Hormone Treatment in GH-Deficient Adults”,The Lancet, pp. 1221-1227 (1989).
Richelsen, et al. “Growth hormone treatment of obese women for 5 wk: effect in body composition and adipose tissue LPL Activity”,Am. J. Physiol, 266, E211-E216, (1994).
Arvat, et al. “Arginine and Growth Hormone-Releasing Hormone Restore the Blunted Growth Hormone-Releasing Activity of Hexarelin in Elderly Subjects”,Journal of Clinical Endocrinology and Metabolism79(5), pp. 1440-1443 (1994).
Aloi, et al. “Neuroendocrine Responses to a Novel Growth Hormone Secretagogue, L-692,429, in Healthy Older Subjects”,Journal of Clinical Endocrinology and Metabolism79(4), pp. 943-949 (1994).
Gertz, et al. “L-692,429, a Nonpeptide Growth Hormone (GH) Secretagogue, Reverses Glucocorticoid Suppression of GH Secretion”,Journal of Clinical Endocrinology and Metabolism, 79 (3), pp. 745-749 (1994).
Jacks, et al. “Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles”Journal of Endocrinology143, pp. 399-406 (1994).
Rudman, et al. “Effects of Human Growth Hormone on Body Composition in Elderly Men”,Horm Res, 36(suppl. 1), pp. 73-81 (1991).
Carpino Philip Albert
Griffith David Andrew
Lefker Bruce Allen
Pfizer Inc.
Raymond Richard L.
Wichtowski John A.
LandOfFree
Dipeptide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dipeptide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipeptide derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3448488